JP4369258B2 - 免疫賦活剤 - Google Patents
免疫賦活剤 Download PDFInfo
- Publication number
- JP4369258B2 JP4369258B2 JP2004028965A JP2004028965A JP4369258B2 JP 4369258 B2 JP4369258 B2 JP 4369258B2 JP 2004028965 A JP2004028965 A JP 2004028965A JP 2004028965 A JP2004028965 A JP 2004028965A JP 4369258 B2 JP4369258 B2 JP 4369258B2
- Authority
- JP
- Japan
- Prior art keywords
- glucan
- culture
- mass
- lactic acid
- immunostimulant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 64
- 241000894006 Bacteria Species 0.000 claims description 54
- 230000003308 immunostimulating effect Effects 0.000 claims description 36
- 229920001503 Glucan Polymers 0.000 claims description 34
- 235000014655 lactic acid Nutrition 0.000 claims description 32
- 239000004310 lactic acid Substances 0.000 claims description 32
- 229960001438 immunostimulant agent Drugs 0.000 claims description 26
- 239000003022 immunostimulating agent Substances 0.000 claims description 26
- 239000007787 solid Substances 0.000 claims description 15
- 241000194032 Enterococcus faecalis Species 0.000 claims description 14
- 241000879125 Aureobasidium sp. Species 0.000 claims description 13
- 238000012258 culturing Methods 0.000 claims description 9
- 239000004480 active ingredient Substances 0.000 claims description 7
- 241000223678 Aureobasidium pullulans Species 0.000 claims description 5
- 230000000813 microbial effect Effects 0.000 claims 1
- 210000004027 cell Anatomy 0.000 description 24
- 238000012360 testing method Methods 0.000 description 21
- 239000000243 solution Substances 0.000 description 19
- 230000004083 survival effect Effects 0.000 description 13
- 208000015181 infectious disease Diseases 0.000 description 11
- 238000011081 inoculation Methods 0.000 description 11
- 230000001580 bacterial effect Effects 0.000 description 10
- 229940032049 enterococcus faecalis Drugs 0.000 description 10
- 238000000034 method Methods 0.000 description 9
- 239000000126 substance Substances 0.000 description 9
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 8
- FYGDTMLNYKFZSV-URKRLVJHSA-N (2s,3r,4s,5s,6r)-2-[(2r,4r,5r,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5r,6s)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1[C@@H](CO)O[C@@H](OC2[C@H](O[C@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-URKRLVJHSA-N 0.000 description 8
- 229920002498 Beta-glucan Polymers 0.000 description 8
- 210000001744 T-lymphocyte Anatomy 0.000 description 8
- 230000000052 comparative effect Effects 0.000 description 8
- 235000013305 food Nutrition 0.000 description 8
- 210000000952 spleen Anatomy 0.000 description 8
- 241000186779 Listeria monocytogenes Species 0.000 description 7
- 241000699670 Mus sp. Species 0.000 description 7
- 230000004913 activation Effects 0.000 description 7
- 239000003550 marker Substances 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- 241000223651 Aureobasidium Species 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 238000010438 heat treatment Methods 0.000 description 5
- 210000000056 organ Anatomy 0.000 description 5
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- 229960002685 biotin Drugs 0.000 description 4
- 235000020958 biotin Nutrition 0.000 description 4
- 239000011616 biotin Substances 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 4
- 230000037406 food intake Effects 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- 230000036737 immune function Effects 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- 230000001954 sterilising effect Effects 0.000 description 3
- 239000011550 stock solution Substances 0.000 description 3
- 230000002195 synergetic effect Effects 0.000 description 3
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 102100037850 Interferon gamma Human genes 0.000 description 2
- 108010074328 Interferon-gamma Proteins 0.000 description 2
- 241000186781 Listeria Species 0.000 description 2
- 238000000585 Mann–Whitney U test Methods 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 229920001218 Pullulan Polymers 0.000 description 2
- 239000004373 Pullulan Substances 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 238000012869 ethanol precipitation Methods 0.000 description 2
- 235000013373 food additive Nutrition 0.000 description 2
- 239000002778 food additive Substances 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 2
- 235000013402 health food Nutrition 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 230000008076 immune mechanism Effects 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 235000015110 jellies Nutrition 0.000 description 2
- 239000008274 jelly Substances 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 235000019423 pullulan Nutrition 0.000 description 2
- 235000014347 soups Nutrition 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 230000008719 thickening Effects 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229920000310 Alpha glucan Polymers 0.000 description 1
- 239000004382 Amylase Substances 0.000 description 1
- 102000013142 Amylases Human genes 0.000 description 1
- 108010065511 Amylases Proteins 0.000 description 1
- 240000006439 Aspergillus oryzae Species 0.000 description 1
- 235000002247 Aspergillus oryzae Nutrition 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 101000957724 Catostomus commersonii Corticoliberin-1 Proteins 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 102100025137 Early activation antigen CD69 Human genes 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000194033 Enterococcus Species 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- 108010073178 Glucan 1,4-alpha-Glucosidase Proteins 0.000 description 1
- 239000004366 Glucose oxidase Substances 0.000 description 1
- 108010015776 Glucose oxidase Proteins 0.000 description 1
- 239000012981 Hank's balanced salt solution Substances 0.000 description 1
- 101000934374 Homo sapiens Early activation antigen CD69 Proteins 0.000 description 1
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 description 1
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 description 1
- 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 244000294411 Mirabilis expansa Species 0.000 description 1
- 235000015429 Mirabilis expansa Nutrition 0.000 description 1
- 101001044384 Mus musculus Interferon gamma Proteins 0.000 description 1
- 208000031888 Mycoses Diseases 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 235000019418 amylase Nutrition 0.000 description 1
- 239000003674 animal food additive Substances 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000000306 component Substances 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 230000008260 defense mechanism Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 235000013611 frozen food Nutrition 0.000 description 1
- 235000015203 fruit juice Nutrition 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 229940116332 glucose oxidase Drugs 0.000 description 1
- 235000019420 glucose oxidase Nutrition 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000002861 immature t-cell Anatomy 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 230000002584 immunomodulator Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000008944 intestinal immunity Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 238000009630 liquid culture Methods 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 235000013536 miso Nutrition 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 230000003071 parasitic effect Effects 0.000 description 1
- 210000001539 phagocyte Anatomy 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 235000021067 refined food Nutrition 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 235000014214 soft drink Nutrition 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000036962 time dependent Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 235000015192 vegetable juice Nutrition 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
Landscapes
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Description
数式1:β−グルカン(g/100g)=ブドウ糖(g/100g)×0.9
アウレオバシジウム プルランス M-1(Aureobasidium pullulans M-1)(FERM P-19213)の前培養液を、ショ糖1%、アスコルビン酸0.2%、米糠0.2%を含む液体培地(pH5.3)に適量接種して、25℃、2日間、通気撹拌培養を行った。培養終了後、この培養液を121℃、15分間殺菌した。この培養液は固形分1質量%であり、該固形分中に35質量%のβ−1,3−1,6−グルカンを含んでいた。
エンテロコッカス・フェカリス(Enterococcus faecalis、IFO 16803)を、ロゴサ培地で37℃、24時間培養した前培養液を、酵母エキス4%、ポリペプトン3%、乳糖10%を含む液体培地に適量接種し、pHスタットを用いてpH6.8〜7.0に苛性ソーダ水溶液で調整しながら37℃、22〜24時間中和培養を行った。
上記(1)で得られたアウレオバシジウム培養物1Lに、上記(2)で得られた乳酸菌の加熱殺菌菌体10gを加えて、均一に混合して免疫賦活剤を得た。
1週間予備飼育を行ったBALB/cマウス(7週齢、雌)28匹(日本エスエルシー(株)より購入)を4群(各群7匹)に分け、各群に下記の被験物質をマウス1匹当り200μlずつ、1日1回試験期間中連続経口投与した。
比較群1:アウレオバシジウム培養液(実施例1(1)で得られたもの)
比較群2:乳酸菌の加熱殺菌菌体(実施例1(2)で得られたもの)をPBSに懸濁したもの(1g菌体/100ml)
対照群:PBS
上記各被験物質を1週間連続経口投与した各群のマウスの尾静脈内に、細胞内寄生性細菌であるリステリア菌(Listeria monocytogenes、EGD株)を5.4×104cfu/200μl/マウス(2×LD50)となるように接種し、その後2週間経過観察を行い、各群のマウスの生存率及び平均生存期間を求めた。
上記(1)において、リステリア菌に対する感染抵抗性に本免疫賦活剤が作用をしていることが示唆されたため、菌排除の指標となる臓器内菌数の経時的変化について解析を行った。
上記(1)、(2)において、生存率、生存期間及び臓器内菌数に差異が認められたため、リステリア菌に対する感染抵抗性に関与する生体側の細胞に関してフローサイトメータによる解析を行った。
(a)Cy-chrome(Cy)標識抗CD3mAb(T細胞固有認識マーカー)/FITC標識抗TCRαβmAb(T細胞型別認識マーカー)/PE標識抗CD4mAb/biotin標識抗TCRγδ(T細胞型別認識マーカー)mAb
(b)Cy標識抗CD3mAb/FITC標識抗TCRαβmAb/PE標識抗CD4mAb/biotin標識抗CD69mAb(早期活性化マーカー)
(c)Cy標識抗CD3mAb/FITC標識抗TCRαβmAb/PE標識抗CD4mAb/biotin標識抗CD25mAb(IL-2Rα;活性化マーカー)
(d)Cy標識抗CD3mAb/FITC標識抗TCRαβmAb/PE標識抗CD122mAb(IL-2Rβ;活性化マーカー)/biotin標識抗CD4mAb
Claims (4)
- アウレオバシジウム属(Aureobasidium sp.)に属する菌を培養して得られるβ−1,3−1,6−グルカンを含む培養物と、乳酸菌エンテロコッカス・フェカリス(Enterococcus faecalis)の加熱処理菌体とを有効成分として含有することを特徴とする免疫賦活剤。
- 前記アウレオバシジウム属(Aureobasidium sp.)に属する菌は、アウレオバシジウム プルランス M-1(Aureobasidium pullulans M-1)(FERM P-19213)である、請求項1に記載の免疫賦活剤。
- 固形分中に、前記培養物をβ−1,3−1,6−グルカン換算で5〜80質量%含有し、かつ前記乳酸菌菌体を10〜80質量%含有する、請求項1又は2に記載の免疫賦活剤。
- 前記培養物は、固形分濃度が0.5〜5質量%であり、かつ、固形分中にβ−1,3−1,6−グルカンを10質量%以上含むものである、請求項1〜3のいずれか一つに記載の免疫賦活剤。
Priority Applications (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2004028965A JP4369258B2 (ja) | 2004-02-05 | 2004-02-05 | 免疫賦活剤 |
CNB2004800010385A CN100341521C (zh) | 2003-03-07 | 2004-03-04 | 含β-葡聚糖的组合物 |
KR1020057004241A KR100649855B1 (ko) | 2003-03-07 | 2004-03-04 | β-글루칸 함유 조성물 및 상기 조성물을 이용한 변비개선제, 면역 부활제 및 피부용 보습제 |
PCT/JP2004/002780 WO2004078188A1 (ja) | 2003-03-07 | 2004-03-04 | βーグルカン含有組成物及び該組成物を利用した便秘改善剤、免疫賦活剤並びに皮膚用保湿剤 |
AT04717235T ATE519490T1 (de) | 2003-03-07 | 2004-03-04 | Zusammensetzung mit beta-glucan und obstipationslinderndes mittel, immunopotentiator und hautbefeuchtungsmittel unter verwendung der zusammensetzung |
US10/531,463 US20050272694A1 (en) | 2003-03-07 | 2004-03-04 | Composition containing beta-glucan and constipation-relieving drug, immunopotentiatior, and skin moistening agent using the composition |
EP04717235A EP1602377B1 (en) | 2003-03-07 | 2004-03-04 | Composition containing beta-glucan and constipation-relieving drug, immunopotentiator and skin moistening agent using the composition |
TWCOMPOSITIA TWI282279B (en) | 2003-03-07 | 2004-03-05 | A61p 37/04 200601 a i vhtw a61p 17/16 200601 a i vhtw |
HK06103700A HK1083590A1 (en) | 2003-03-07 | 2006-03-24 | Composition containing beta-glucan |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2004028965A JP4369258B2 (ja) | 2004-02-05 | 2004-02-05 | 免疫賦活剤 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2005220065A JP2005220065A (ja) | 2005-08-18 |
JP4369258B2 true JP4369258B2 (ja) | 2009-11-18 |
Family
ID=34995976
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2004028965A Expired - Lifetime JP4369258B2 (ja) | 2003-03-07 | 2004-02-05 | 免疫賦活剤 |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP4369258B2 (ja) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20190083699A (ko) | 2018-01-05 | 2019-07-15 | 가부시키가이샤 아우레오 | 트롬보스폰딘 1 유전자 발현 항진용 조성물 |
WO2021049587A1 (ja) | 2019-09-11 | 2021-03-18 | 株式会社アウレオ | 抗体医薬の効果増強用組成物 |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2007297322A (ja) * | 2006-04-28 | 2007-11-15 | Toyobo Co Ltd | サイトカイン産生の促進方法 |
JP5072286B2 (ja) * | 2006-08-25 | 2012-11-14 | 株式会社林原 | 動物の免疫調節剤 |
KR20090009513A (ko) * | 2007-07-20 | 2009-01-23 | 한국원자력연구원 | 방사선 조사에 의한 저 분자량의 베타글루칸의 제조 방법및 방사선 조사에 의하여 제조된 저 분자량의 베타글루칸 |
JP5585769B2 (ja) * | 2009-05-15 | 2014-09-10 | ダイソー株式会社 | 腸管免疫賦活能を有する乳酸菌に対する効果促進剤 |
TWI482642B (zh) * | 2009-05-27 | 2015-05-01 | 用於減敏療法之免疫調節製劑組合物及其劑型結構 | |
TWI496578B (zh) * | 2009-10-08 | 2015-08-21 | Aureo Co Ltd | 流感病毒感染症的治療劑 |
JP5554221B2 (ja) * | 2010-12-13 | 2014-07-23 | 株式会社アウレオ | ウシの乳房炎の予防・治療用組成物及びウシの乳房炎の予防・治療方法 |
WO2014013793A1 (ja) * | 2012-07-17 | 2014-01-23 | Miura Shigenobu | βグルカンの製造方法 |
JP2016079118A (ja) * | 2014-10-15 | 2016-05-16 | 株式会社Adeka | 免疫調節剤、健康補助飼料及び飼料 |
JP2018016580A (ja) * | 2016-07-27 | 2018-02-01 | 株式会社東洋発酵 | 免疫賦活組成物 |
JP2018076715A (ja) * | 2016-11-10 | 2018-05-17 | 大阪瓦斯株式会社 | 石油増進回収方法 |
JP6914534B2 (ja) * | 2018-08-30 | 2021-08-04 | 株式会社アウレオ | β−グルカン高産生菌株、β−グルカンの製造方法、及びβ−グルカン高産生菌株のスクリーニング方法 |
-
2004
- 2004-02-05 JP JP2004028965A patent/JP4369258B2/ja not_active Expired - Lifetime
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20190083699A (ko) | 2018-01-05 | 2019-07-15 | 가부시키가이샤 아우레오 | 트롬보스폰딘 1 유전자 발현 항진용 조성물 |
WO2021049587A1 (ja) | 2019-09-11 | 2021-03-18 | 株式会社アウレオ | 抗体医薬の効果増強用組成物 |
Also Published As
Publication number | Publication date |
---|---|
JP2005220065A (ja) | 2005-08-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Saadat et al. | A comprehensive review of anticancer, immunomodulatory and health beneficial effects of the lactic acid bacteria exopolysaccharides | |
KR100649855B1 (ko) | β-글루칸 함유 조성물 및 상기 조성물을 이용한 변비개선제, 면역 부활제 및 피부용 보습제 | |
JP5737646B2 (ja) | 抗アレルギー剤 | |
JP4369258B2 (ja) | 免疫賦活剤 | |
AU2016344136B2 (en) | Use of beta-1,3-glucan for modulating immune function and treating intestinal inflammation | |
US20050271613A1 (en) | Beta-1, 3-1, 6-D-glucan and its use | |
JPWO2007013613A1 (ja) | フコイダン又はフコイダン加水分解生成物と免疫賦活素材とを含む組成物 | |
JP2020512837A (ja) | 消化器の健康、体重管理、免疫の強化および健康の改善のためのマルチ繊維プレバイオティクス組成物 | |
JP5337535B2 (ja) | Nk活性増強剤 | |
JP5585769B2 (ja) | 腸管免疫賦活能を有する乳酸菌に対する効果促進剤 | |
JP2020092704A (ja) | 新規な乳酸菌株およびそれを含む免疫賦活剤 | |
JP4499979B2 (ja) | 病原菌感染抑制用組成物 | |
WO2017145415A1 (ja) | 免疫発達促進剤 | |
JP4054697B2 (ja) | 便秘改善剤 | |
JP4064515B2 (ja) | Il−12産生誘導組成物 | |
JP6842014B2 (ja) | トロンボスポンジン1遺伝子発現亢進用組成物 | |
US20060178340A1 (en) | Composition comprising soluble glucan oligomer from saccharomyces cerevisiae is2 for immune activation or prevention and treatment of cancer and the preparation method thereof | |
JP7330854B2 (ja) | ビフィズス菌増殖用組成物 | |
JP5560472B2 (ja) | インフルエンザウイルス感染症の治療剤 | |
CN114340669A (zh) | 用于增强抗体药物的效果的组合物 | |
TWI230611B (en) | Anti-infection composition and food containing such anti-infection composition | |
JP4369099B2 (ja) | 腫瘍壊死因子の産生誘導組成物 | |
JP2005060288A (ja) | 免疫賦活剤及び抗腫瘍剤 | |
JP2005035896A (ja) | 免疫賦活剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20050728 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20090421 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20090622 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20090622 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20090804 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20090827 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 4369258 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120904 Year of fee payment: 3 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120904 Year of fee payment: 3 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130904 Year of fee payment: 4 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
S531 | Written request for registration of change of domicile |
Free format text: JAPANESE INTERMEDIATE CODE: R313531 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
EXPY | Cancellation because of completion of term |